Medicenna Therapeutics Corp - MDNA STOCK NEWS

Medicenna Therapeutics Corp. (NASDAQ: MDNA) announced its financial results for the quarter ending December 31, 2021. Key highlights include preliminary data from the Phase 1/2 ABILITY study of MDNA11, which demonstrated significant biological activity and a well-tolerated safety profile. The company is on track to release further efficacy results by mid-2022. Additionally, Medicenna had cash reserves of $23.4 million, sufficient to fund operations through the end of 2022, while net losses decreased to $4.8 million compared to $5.3 million in 2020.

Medicenna Therapeutics Corp. (NASDAQ: MDNA, TSX: MDNA) will host a conference call and live webcast on February 9, 2022, at 8:30 AM ET to discuss its third quarter fiscal 2022 financial results and operational highlights. Investors can dial in or access the event online. Medicenna is focused on developing immunotherapies like its IL-2 Superkine, MDNA11, and IL-4 Empowered Superkine, MDNA55, which has received Fast-Track and Orphan Drug designations from the FDA. Further information will be made available following the live broadcast.

Medicenna Therapeutics Corp. (NASDAQ: MDNA TSX: MDNA) has formed a Scientific Advisory Board (SAB) to enhance its immunotherapy initiatives. Chaired by Dr. Sergio Quezada, the SAB includes prominent experts in cancer immunotherapy and immune monitoring. The board aims to propel the development of Medicenna’s Superkine platform, targeting innovative treatments for cancer and immune-related diseases. Dr. Fahar Merchant, President and CEO, expressed optimism about leveraging the collective expertise of the SAB to advance ongoing clinical studies and future candidates derived from their platforms.

Medicenna announced peer-reviewed publication results for MDNA11, a selective IL-2 super-agonist, showing a 30-fold increase in binding affinity for the IL-2 receptor beta compared to recombinant human IL-2. Preclinical data indicate MDNA11 is well-tolerated and enhances anti-cancer immune cell proliferation with minimal pro-tumor stimulation. In murine models, it generated durable tumor responses and long-term protection. The ABILITY study for patients with advanced tumors is ongoing, with updates expected in early 2022.

Medicenna Therapeutics (NASDAQ: MDNA) announced that its Phase 1/2 ABILITY study of MDNA11 is on track for updates in Q1 2022 regarding safety, pharmacokinetics, and initial efficacy results. Following the resignation of Mann Muhsin as Chief Medical Officer, Martin Bexon, who has been with the company since 2016, will serve as Acting CMO. The company has also strengthened its Development Advisory Committee with experienced industry professionals to maximize the potential of MDNA11 and its pipeline of BiSKITs™.

Medicenna Therapeutics Corp. (NASDAQ: MDNA; TSX: MDNA) announced participation in several virtual investor conferences in January 2022. Key events include the 11th Annual LifeSci Partners Corporate Access Event from January 5-7, featuring a panel on immune-oncology on January 7 at 7:30 a.m. ET. The H.C. Wainwright BIOCONNECT Virtual Conference runs from January 10-13, starting with an on-demand presentation. Additionally, the Biotech Showcase™ will take place from January 10-12 and 17-19, focusing on one-on-one investor meetings.

Medicenna Therapeutics Corp. (NASDAQ: MDNA) announced promising preliminary results from the Phase 1/2 ABILITY study of MDNA11, its novel, long-acting IL-2 super-agonist. Key findings indicate a ~2-3 fold increase in the CD8⁺ T cell to Treg ratio, suggesting enhanced anti-tumor activity. The treatment showed a favorable safety profile with no dose-limiting toxicities or serious adverse effects. The company plans to provide further updates in the coming quarter and anticipates initial efficacy results by mid-2022.

Medicenna Therapeutics announced the expansion of its Phase 1/2 ABILITY study for MDNA11, a long-acting IL-2 super-agonist, to include clinical trial sites in Canada. This follows prior FDA clearance for sites in the U.S. Preliminary safety and pharmacokinetic/pharmacodynamic data are expected by year-end 2021, with initial efficacy data anticipated in mid-2022. The study aims to assess MDNA11's safety, PK, PD, and anti-tumor activity, enrolling approximately 80 patients with advanced solid tumors. Medicenna also plans potential expansion to the U.K. if necessary.